Novolin
It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it. The article may be deleted if this message remains in place for seven days, i.e., after 14:08, 26 June 2025 (UTC). Find sources: "Novolin" – news · newspapers · books · scholar · JSTOR |
Novolin is the brand name of three distinct insulin-containing products[1] manufactured by Novo Nordisk:[2]
- Novolin 70/30, an insulin preparation containing mixed NPH and regular insulin, respectively
- Novolin N, an insulin preparation containing NPH insulin
- Novolin R, an insulin preparation containing regular insulin
References
[edit]- ^ "Novolin N Uses, Side Effects & Warnings". Drugs.com. Retrieved 4 May 2022.
- ^ Landgraf W, Sandow J (March 2016). "Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy". European Endocrinology. 12 (1): 12–17. doi:10.17925/EE.2016.12.01.12. PMC 5813452. PMID 29632581.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |